Compass Pathways (NASDAQ: CMPS) has announced plans to reduce its workforce by approximately 30% and halt early-stage research programs, as the company intensifies its focus on the late-stage development of its lead candidate, the COMP360 psilocybin therapy. The London-based mental health company revealed its restructuring strategy alongside its third-quarter financial results, which highlighted an increased…